Eli Lil­ly aban­dons its plans to pitch its block­buster con­tender mirik­izum­ab for pso­ri­a­sis af­ter siz­ing up heavy­weight ri­vals

Last Ju­ly, Eli Lil­ly ex­ecs had noth­ing but good things to say about the “promis­ing” late-stage pso­ri­a­sis da­ta they had gath­ered to­geth­er on their IL23 drug mirik­izum­ab. The drug had hit the pri­ma­ry and all key sec­ondary end­points, and they were get­ting ready to roll it out to the FDA and reg­u­la­to­ry agen­cies around the world.

“We look for­ward to bring­ing mirik­izum­ab to mar­ket to pro­vide pa­tients with an ad­di­tion­al treat­ment op­tion that has the po­ten­tial to pro­vide near com­plete or com­plete skin clear­ance as mea­sured by PASI 90 and PASI 100, with sus­tained re­sults at 52 weeks,” Lil­ly USA pres­i­dent Pa­trik Jon­s­son not­ed at the time, as the com­pa­ny beamed over its head-to-head win over Cosen­tyx, the ri­val drug every­one de­vel­op­ing new ther­a­pies likes to test against.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER